Advanced

Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers

Ottervald, Jan; Franzen, Bo; Nilsson, Kerstin; Andersson, Lars I.; Khademi, Mohsen; Eriksson, Bodil; Kjellstrom, Sven; Marko-Varga, György LU ; Végvári, Ákos LU and Harris, Robert A., et al. (2010) In Journal of Proteomics2008-01-01+01:00 73(6). p.1117-1132
Abstract
Multiple sclerosis (MS) is a neuro-inflammatory and neurodegenerative disease that results in damage to myelin sheaths and axons in the central nervous system and which preferentially affects young adults. We performed a proteomics-based biomarker discovery study in which cerebrospinal fluid (CSF) from MS and control individuals was analyzed (n=112). Ten candidate biomarkers were selected for evaluation by quantitative immunoassay using an independent cohort of MS and control subjects (n=209). In relapsing remitting MS (ARMS) patients there were significant increases in the CSF levels of alpha-1 antichymotrypsin (A1AC), alpha-1 macroglobulin (A2MG) and fibulin 1 as compared to control subjects. In secondary progressive MS (SPMS) four... (More)
Multiple sclerosis (MS) is a neuro-inflammatory and neurodegenerative disease that results in damage to myelin sheaths and axons in the central nervous system and which preferentially affects young adults. We performed a proteomics-based biomarker discovery study in which cerebrospinal fluid (CSF) from MS and control individuals was analyzed (n=112). Ten candidate biomarkers were selected for evaluation by quantitative immunoassay using an independent cohort of MS and control subjects (n=209). In relapsing remitting MS (ARMS) patients there were significant increases in the CSF levels of alpha-1 antichymotrypsin (A1AC), alpha-1 macroglobulin (A2MG) and fibulin 1 as compared to control subjects. In secondary progressive MS (SPMS) four additional proteins (contactin 1, fetuin A, vitamin D binding protein and angiotensinogen (ANGT)) were increased as compared to control subjects. In particular, ANGT was increased 3-fold in SPMS, indicating a potential as biomarker of disease progression in MS. In PPMS, A1AC and A2MG exhibit significantly higher CSF levels than controls, with a trend of increase for ANGT. Classification models based on the biomarker panel could identify 70% of the RRMS and 80% of the SPMS patients correctly. Further evaluation was conducted in a pilot study of CSF from RRMS patients (n=36), before and after treatment with natalizumab. (C) 2010 Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Treatment, Prognosis, Biomarkers, Proteomics, Multiple sclerosis, CSF
in
Journal of Proteomics2008-01-01+01:00
volume
73
issue
6
pages
1117 - 1132
publisher
Elsevier
external identifiers
  • wos:000277763800009
  • scopus:77950597049
ISSN
1874-3919
DOI
10.1016/j.jprot.2010.01.004
language
English
LU publication?
yes
id
481d1f1d-f0cc-4ba7-90d7-caac88204ef9 (old id 1617444)
date added to LUP
2010-06-24 08:51:35
date last changed
2018-09-09 03:24:21
@article{481d1f1d-f0cc-4ba7-90d7-caac88204ef9,
  abstract     = {Multiple sclerosis (MS) is a neuro-inflammatory and neurodegenerative disease that results in damage to myelin sheaths and axons in the central nervous system and which preferentially affects young adults. We performed a proteomics-based biomarker discovery study in which cerebrospinal fluid (CSF) from MS and control individuals was analyzed (n=112). Ten candidate biomarkers were selected for evaluation by quantitative immunoassay using an independent cohort of MS and control subjects (n=209). In relapsing remitting MS (ARMS) patients there were significant increases in the CSF levels of alpha-1 antichymotrypsin (A1AC), alpha-1 macroglobulin (A2MG) and fibulin 1 as compared to control subjects. In secondary progressive MS (SPMS) four additional proteins (contactin 1, fetuin A, vitamin D binding protein and angiotensinogen (ANGT)) were increased as compared to control subjects. In particular, ANGT was increased 3-fold in SPMS, indicating a potential as biomarker of disease progression in MS. In PPMS, A1AC and A2MG exhibit significantly higher CSF levels than controls, with a trend of increase for ANGT. Classification models based on the biomarker panel could identify 70% of the RRMS and 80% of the SPMS patients correctly. Further evaluation was conducted in a pilot study of CSF from RRMS patients (n=36), before and after treatment with natalizumab. (C) 2010 Elsevier B.V. All rights reserved.},
  author       = {Ottervald, Jan and Franzen, Bo and Nilsson, Kerstin and Andersson, Lars I. and Khademi, Mohsen and Eriksson, Bodil and Kjellstrom, Sven and Marko-Varga, György and Végvári, Ákos and Harris, Robert A. and Laurell, Thomas and Miliotis, Tasso and Matusevicius, Darius and Salter, Hugh and Ferm, Mats and Olsson, Tomas},
  issn         = {1874-3919},
  keyword      = {Treatment,Prognosis,Biomarkers,Proteomics,Multiple sclerosis,CSF},
  language     = {eng},
  number       = {6},
  pages        = {1117--1132},
  publisher    = {Elsevier},
  series       = {Journal of Proteomics2008-01-01+01:00},
  title        = {Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers},
  url          = {http://dx.doi.org/10.1016/j.jprot.2010.01.004},
  volume       = {73},
  year         = {2010},
}